Study S001915

A Phase 2, Parallel-Group, Double-Blind, 4-Arm Study to Investigate Weight Management With LY3305677 Compared With Placebo and in Adult Participants With Obesity or Overweight

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT06124807
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 179
Start: 2023-11-17
Primary completion: 2025-01-22
Lead sponsor: Eli Lilly and Company
Conditions: Obesity; Overweight and Obesity
Interventions: DRUG:Mazdutide; DRUG:Placebo
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:W8M-MC-OXA1; OTHER:CWMM Master Protocol

Registered primary outcomes

Percent Change From Baseline in Body Weight at Week 32 [Baseline, Week 32]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0010399	Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial. Hsia SH, The lancet. Diabetes & endocrinology	2026	Randomized trial	PMID 42628555 DOI	cites ClinicalTrials.gov:NCT06124807; registry reference DERIVED:42628555
R0045097	1733-P: Effect of Mazdutide on Kidney Function in Adults with Obesity or Overweight STANLEY HSIA, Diabetes	2026	Randomized trial	DOI	cites ClinicalTrials.gov:NCT06124807
R0053554	1693-P: Mazdutide Improves Markers of Insulin Sensitivity in Adults with Obesity without Type 2 Diabetes MELISSA THOMAS, Diabetes	2026	Other trial	DOI	cites ClinicalTrials.gov:NCT06124807